Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>Products>This Product
  Products


MaxDiscovery™ Respiratory Syncytial Virus (RSV) ELISA Kit

Product Description
The MaxDiscovery™ Respiratory Syncytial Virus (RSV) ELISA Kit is an enzyme immunoassay designed for research use only that quantifies Respiratory Syncytial Virus or RSV from cells or fluid samples. Respiratory Syncytial Virus is a very common virus that leads to mild, cold-like symptoms in adults and older healthy children. Most otherwise healthy people recover from RSV infection in 1 to 2 weeks. However, infection can be severe in some people, such as certain infants, young children, and older adults. In fact, RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children under 1 year of age in the United States. Like most ELISA assays, the MaxDiscovery™ Respiratory Syncytial Virus ELISA Kit relies on a Horseradish Perioxidase (HRP) conjugated antibody and the TMB (3,3´,5,5´-tetramethylbenzidine) substrate. TMB is a chromogen that is blue when oxidized with hydrogen peroxide (catalyzed by HRP) and has major absorbance peaks at 370 nm and 652 nm. The color changes to yellow with the addition of acid and has a maximum absorbance at 450 nm. The relative amount of Respiratory Syncytial Virus protein is directly proportional to the optical density (OD) reading at 450 nm. This kit contains materials for the quantitative detection of the RSV protein in human cells or fluid samples. Note: This kit is designed for research use only. All US orders require that a "Research Use Only" certification form (download below) must be filled out and submitted with your order.
Product MaxDiscovery™ Respiratory Syncytial Virus (RSV) ELISA Kit
Company BIOO Scientific - Product Directory
Price Request a quote
More Information View company product page
Catalog Number 1 x 96 wells
Quantity 345
Company Logo

BIOO Scientific - Product Directory
3913 Todd Lane Suite 312 Austin, TX 78744, USA

Tel: +1 512-707-8993
Fax: +1 512-707-8122
Email: info@biooscientific.com



Scientific News
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.

SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!